SCHEMBL498587

SCHEMBL498587

CCCCOc1cc(CBr)ccc1C(=O)OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.47
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 3/20 0.46
HPGD P15428 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HTT P42858 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
TP53 P04637 2/20 0.43
GAA P10253 2/20 0.43
TSHR P16473 2/20 0.43
FFAR4 Q5NUL3 1/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HSP90AA1 P07900 1/20 0.43
MAPT P10636 1/20 0.43
CYP1A2 P05177 3/20 0.43
CYP2C19 P33261 1/20 0.43
CYP4F2 P78329 2/20 0.43
CYP4A11 Q02928 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2770100 0.90 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDL3MBTL1HTT
SCHEMBL3061455 0.90 MAPT (0.45) TDP1ALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL9395485 0.89 TSHR (0.54) TDP1ALDH1A1KDM4EL3MBTL1SMN1; SMN2
SCHEMBL497755 0.87 ALDH1A1 (0.50) TDP1ALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL14035640 0.84 TDP1 (0.46) TDP1ALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL9122410 0.84 TDP1 (0.45) TDP1ALDH1A1KDM4EHPGDHTT
SCHEMBL2772618 0.83 HTT (0.48) ALDH1A1KDM4EHPGDHTTSMN1; SMN2
SCHEMBL15198836 0.82 TDP1 (0.49) TDP1ALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL16482859 0.82 MAOA (0.54) TDP1ALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL498071 0.81 HTT (0.63) TDP1ALDH1A1KDM4EHPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106077-B2 Compounds and methods for modulating FXR ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
US-7846960-B2 FXR agonists ELI LILLY AND COMPANY (US) 2010-12-07 US disclosed
EP-2029547-B1 FXR AGONISTS LILLY CO ELI (US) 2010-04-28 EP disclosed
EP-2029558-B1 COMPOUNDS AND METHODS FOR MODULATING FXR LILLY CO ELI (US) 2010-03-10 EP disclosed
US-20090270460-A1 FXR AGONISTS JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2009-10-29 US disclosed
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2009-04-09 US disclosed
EP-2029547-A1 FXR AGONISTS ELI LILLY AND COMPANY (US) 2009-03-04 EP disclosed
EP-2029558-A2 COMPOUNDS AND METHODS FOR MODULATING FXR ELI LILLY AND COMPANY (US) 2009-03-04 EP disclosed
WO-2007140183-A1 FXR AGONISTS ELI LILLY AND COMPANY (US) 2007-12-06 WO disclosed
WO-2007140174-A2 COMPOUNDS AND METHODS FOR MODULATING FXR ELI LILLY AND COMPANY (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270460-A1 FXR AGONISTS NR1H4, SLC10A1, GPBAR1 TDP1 4431/4885ALDH1A1 2072/4885KDM4E 4469/4885
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NR1H4, SLC10A1, FXR1 TDP1 4603/4885ALDH1A1 2294/4885KDM4E 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.